Format

Send to

Choose Destination
Stem Cells Dev. 2012 Jul 1;21(10):1822-30. doi: 10.1089/scd.2011.0477. Epub 2011 Nov 11.

Slow-cycling therapy-resistant cancer cells.

Author information

1
Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Abstract

Tumor recurrence after chemotherapy is a major cause of patient morbidity and mortality. Recurrences are thought to be secondary to small subsets of cancer cells that are better able to survive traditional forms of chemotherapy and thus drive tumor regrowth. The ability to isolate and better characterize these therapy-resistant cells is critical for the future development of targeted therapies aimed at achieving more robust and long-lasting responses. Using a novel application for the proliferation marker carboxyfluorescein diacetate, succinimidyl ester (CFSE), we have identified a population of slow-cycling, label-retaining tumor cells in both in vitro sphere cultures and in vivo xenograft models. Strikingly, label-retaining cells exhibit a multifold increase in ability to survive traditional forms of chemotherapy and reenter the cell cycle. Further, we demonstrate the innovative application of CFSE to live sort slow-cycling tumor cells and validate their chemoresistance and tumorigenic potential.

PMID:
21973238
PMCID:
PMC3376467
DOI:
10.1089/scd.2011.0477
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center